Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis

Genes Chromosomes and Cancer

Volumn 47, Issue 4, 2008, Pages 276-287

  Ageberg, Malin ^a,b   Drott, Kristina ^a   Olofsson, Tor ^a   Gullberg, Urban ^a   Lindmark, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DEK NUP214 PROTEIN; HYBRID PROTEIN; INITIATION FACTOR 4E; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL LINEAGE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; LEUKEMOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS;

EID: 40049098812     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20531     Document Type: Article

References (49)

1. Ageberg M, Gullberg U, Lindmark A. 2006. The involvement of cellular proliferation status in the expression of the human proto‐oncogene DEK. Haematologica 91: 268–269.
2. Boer J, Bonten‐Surtel J, Grosveld G. 1998. Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis. Mol Cell Biol 18: 1236–1247.
3. Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M, Muller H. 2006. DEK expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 5: 1202–1207.
4. Casas S, Nagy B, Elonen E, Aventin A, Larramendy ML, Sierra J, Ruutu T, Knuutila S. 2003. Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leuk Lymphoma 44: 1935–1941.
5. Chylicki K, Ehinger M, Svedberg H, Bergh G, Olsson I, Gullberg U. 2000. p53‐mediated differentiation of the erythroleukemia cell line K562. Cell Growth Differ 11: 315–324.
6. Clemens MJ. 2004. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 23: 3180–3188.
7. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. 2001. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J 20: 4547–4559.
8. Collins SJ, Gallo RC, Gallagher RE. 1977. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 270: 347–349.
9. Crans HN, Sakamoto KM. 2001. Transcription factors and translocations in lymphoid and myeloid leukemia. Leukemia 15: 313–331.
10. Deguchi K, Gilliland DG. 2002. Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia 16: 740–744.
11. Edvardsson L, Dykes J, Olsson ML, Olofsson T. 2004. Clonogenicity, gene expression and phenotype during neutrophil versus erythroid differentiation of cytokine‐stimulated CD34+ human marrow cells in vitro. Br J Haematol 127: 451–463.
12. Fornerod M, Boer J, van Baal S, Jaegle M, von Lindern M, Murti KG, Davis D, Bonten J, Buijs A, Grosveld G. 1995. Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia‐specific chromosome rearrangements. Oncogene 10: 1739–1748.
13. Fu GK, Grosveld G, Markovitz DM. 1997. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV‐2 enhancer. Proc Natl Acad Sci USA 94: 1811–1815.
14. Garcon L, Libura M, Delabesse E, Valensi F, Asnafi V, Berger C, Schmitt C, Leblanc T, Buzyn A, Macintyre E. 2005. DEK‐CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Leukemia 19: 1338–1344.
15. Ghannam G, Takeda A, Camarata T, Moore MA, Viale A, Yaseen NR. 2004. The oncogene Nup98‐HOXA9 induces gene transcription in myeloid cells. J Biol Chem 279: 866–875.
16. Ginzinger DG. 2002. Gene quantification using real‐time quantitative PCR: An emerging technology hits the mainstream. Exp Hematol 30: 503–512.
17. Grottke C, Mantwill K, Dietel M, Schadendorf D, Lage H. 2000. Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer 88: 535–546.
18. Hu HG, Illges H, Gruss C, Knippers R. 2005. Distribution of the chromatin protein DEK distinguishes active and inactive CD21/CR2 gene in pre‐ and mature B lymphocytes. Int Immunol 17: 789–796.
19. Kappes F, Scholten I, Richter N, Gruss C, Waldmann T. 2004. Functional domains of the ubiquitous chromatin protein DEK. Mol Cell Biol 24: 6000–6010.
20. Kasper LH, Brindle PK, Schnabel CA, Pritchard CE, Cleary ML, van Deursen JM. 1999. CREB binding protein interacts with nucleoporin‐specific FG repeats that activate transcription and mediate NUP98‐HOXA9 oncogenicity. Mol Cell Biol 19: 764–776.
21. Kleijn M, Scheper GC, Voorma HO, Thomas AA. 1998. Regulation of translation initiation factors by signal transduction. Eur J Biochem 253: 531–544.
22. Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S, Goseki N, Matsubara O, Takenaka K, Shichita M, Tanaka K, Shuda M, Yamamoto M. 1999. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 59: 4990–4996.
23. Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma J, Moskal JR. 2000. The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett 156: 191–198.
24. Lanotte M, Martin‐Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. 1991. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080–1086.
25. Larramendy ML, Niini T, Elonen E, Nagy B, Ollila J, Vihinen M, Knuutila S. 2002. Overexpression of translocation‐associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis. Haematologica 87: 569–577.
26. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. 2000. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407: 592–598.
27. Lennartsson A, Pieters K, Ullmark T, Vidovic K, Gullberg U. 2003. AML‐1, PU. 1, and Sp3 regulate expression of human bactericidal/permeability‐increasing protein. Biochem Biophys Res Commun 311: 853–863.
28. Lennartsson A, Garwicz D, Lindmark A, Gullberg U. 2005. The proximal promoter of the human cathepsin G gene conferring myeloid‐specific expression includes C/EBP, c‐myb and PU. 1 binding sites. Gene 356: 193–202.
29. Look AT. 1997. Oncogenic transcription factors in the human acute leukemias. Science 278: 1059–1064.
30. Lozzio CB, Lozzio BB. 1975. Human chronic myelogenous leukemia cell‐line with positive Philadelphia chromosome. Blood 45: 321–334.
31. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. 2004. eIF4E—From translation to transformation. Oncogene 23: 3172–3179.
32. Meric F, Hunt KK. 2002. Translation initiation in cancer: A novel target for therapy. Mol Cancer Ther 1: 971–979.
33. Parcells BW, Ikeda AK, Simms‐Waldrip T, Moore TB, Sakamoto KM. 2006. FMS‐like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 24: 1174–1184.
34. Peterson LF, Zhang DE. 2004. The 8;21 translocation in leukemogenesis. Oncogene 23: 4255–4262.
35. Proud CG. 1992. Protein phosphorylation in translational control. Curr Top Cell Regul 32: 243–369.
36. Rajasekhar VK, Holland EC. 2004. Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene 23: 3248–3264.
37. Relander T, Karlsson S, Richter J. 2002. Oncoretroviral gene transfer to NOD/SCID repopulating cells using three different viral envelopes. J Gene Med 4: 122–132.
38. Sundstrom C, Nilsson K. 1976. Establishment and characterization of a human histiocytic lymphoma cell line (U‐937). Int J Cancer 17: 565–577.
39. Svensson E, Eriksson H, Gekas C, Olofsson T, Richter J, Gullberg U. 2005. DNA‐binding dependent and independent functions of WT1 protein during human hematopoiesis. Exp Cell Res 308: 211–221.
40. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T. 2002. Analysis of FLT3‐activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326–4335.
41. Topisirovic I, Culjkovic B, Cohen N, Perez JM, Skrabanek L, Borden KL. 2003. The proline‐rich homeodomain protein, PRH, is a tissue‐specific inhibitor of eIF4E‐dependent cyclin D1 mRNA transport and growth. EMBO J 22: 689–703.
42. Topisirovic I, Ruiz‐Gutierrez M, Borden KL. 2004. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 64: 8639–8642.
43. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, de Belle I. 2001. The Egr‐1 transcription factor directly activates PTEN during irradiation‐induced signalling. Nat Cell Biol 3: 1124–1128.
44. von Lindern M, Fornerod M, Soekarman N, van Baal S, Jaegle M, Hagemeijer A, Bootsma D, Grosveld G. 1992. Translocation t(6;9) in acute non‐lymphocytic leukaemia results in the formation of a DEK‐CAN fusion gene. Baillieres Clin Haematol 5: 857–879.
45. Waldmann T, Baack M, Richter N, Gruss C. 2003. Structure‐specific binding of the proto‐oncogene protein DEK to DNA. Nucleic Acids Res 31: 7003–7010.
46. Wang YL, Wang T, Xu F, Gang Y, Wang J. 2006. [Analysis of DEK‐CAN fusion gene expression in acute myeloid leukemia patients with 6; 9 chromosome translocation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 14: 232–236.
47. Wise‐Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. 2006. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 26: 7506–7519.
48. Wong S, Witte ON. 2004. The BCR‐ABL story: Bench to bedside and back. Annu Rev Immunol 22: 247–306.
49. Yan M, Burel SA, Peterson LF, Kanbe E, Iwasaki H, Boyapati A, Hines R, Akashi K, Zhang DE. 2004. Deletion of an AML1‐ETO C‐terminal NcoR/SMRT‐interacting region strongly induces leukemia development. Proc Natl Acad Sci USA 101: 17186–17191.